<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Parvovirus B19 is a small <z:chebi fb="0" ids="9160">single-stranded DNA</z:chebi> virus and a potent inhibitor of erythropoiesis due to its cytotoxicity to erythroid progenitor cells </plain></SENT>
<SENT sid="1" pm="."><plain>Although <z:e sem="disease" ids="C0277562" disease_type="Disease or Syndrome" abbrv="">adult disease</z:e> is generally mild, fetal <z:e sem="disease" ids="C0085273" disease_type="Disease or Syndrome" abbrv="">parvovirus B19 infection</z:e> can cause <z:hpo ids='HP_0005268'>spontaneous abortion</z:hpo> in early pregnancy and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0001790'>nonimmune hydrops fetalis</z:hpo> and in utero fetal demise </plain></SENT>
<SENT sid="2" pm="."><plain>The prevalence of parvovirus B19 maternal <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> during pregnancy is about 1-2% </plain></SENT>
<SENT sid="3" pm="."><plain>The vertical transmission occurs in 10-35%, being highest in the first and second trimesters </plain></SENT>
<SENT sid="4" pm="."><plain>The risk of adverse fetal outcome is 10% </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast to the second or third trimester, in pregnancies affected by <z:hpo ids='HP_0010880'>increased nuchal translucency</z:hpo> (NT) in the late first trimester, the prevalence of maternal <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> was not higher than in the general population </plain></SENT>
<SENT sid="6" pm="."><plain>We report a case of first-trimester <z:e sem="disease" ids="C0085273" disease_type="Disease or Syndrome" abbrv="">parvovirus B19 infection</z:e> with increased NT and reversed a-wave in the ductus venosus (DV) at 11 weeks, with fetal demise 2 weeks later </plain></SENT>
</text></document>